Renin angiotensin system deregulation as renal cancer risk factor (Review)
- Authors:
- Paweł Sobczuk
- Cezary Szczylik
- Camillo Porta
- Anna M. Czarnecka
-
Affiliations: Department of Oncology, Military Institute of Medicine, 04‑141 Warsaw, Poland, Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, I‑27100 Pavia, Italy - Published online on: August 25, 2017 https://doi.org/10.3892/ol.2017.6826
- Pages: 5059-5068
-
Copyright: © Sobczuk et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Lopez-Beltran A, Scarpelli M, Montironi R and Kirkali Z: 2004 WHO classification of the renal tumors of the adults. Eur Urol. 49:798–805. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C and Czarnecka AM: Choosing the right cell line for renal cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI | |
|
Rydzanicz M, Wrzesinski T, Bluyssen HA and Wesoly J: Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications. Cancer Lett. 341:111–126. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
George AJ, Thomas WG and Hannan RD: The renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev Cancer. 10:745–759. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Miyajima A, Kosaka T, Kikuchi E and Oya M: Renin-angiotensin system blockade: Its contribution and controversy. Int J Urol. 22:721–730. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millán S and Sánchez-Corona J: The renin-angiotensin system meets the hallmarks of cancer. J Renin Angiotensin Aldosterone Syst. 16:227–233. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Derosa L, Izzedine H, Albiges L and Escudier B: Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma. Oncol Rev. 10:2982016. View Article : Google Scholar : PubMed/NCBI | |
|
Yin G, Yan C and Berk BC: Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol. 35:780–783. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, et al: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res. 87:E1–E9. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G and Turner AJ: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 275:33238–33243. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuo JL and Li XC: New insights and perspectives on intrarenal renin-angiotensin system: Focus on intracrine/intracellular angiotensin II. Peptides. 32:1551–1565. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Norwood VF, Craig MR, Harris JM and Gomez RA: Differential expression of angiotensin II receptors during early renal morphogenesis. Am J Physiol. 272:R662–R668. 1997.PubMed/NCBI | |
|
Arendshorst WJ, Brännström K and Ruan X: Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol. 10 Suppl 11:S149–S161. 1999.PubMed/NCBI | |
|
Matsubara H, Sugaya T, Murasawa S, Nozawa Y, Mori Y, Masaki H, Maruyama K, Tsutumi Y, Shibasaki Y, Moriguchi Y, et al: Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in adult human renal cortex using in situ hybridization. Nephron. 80:25–34. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Goldfarb DA, Diz DI, Tubbs RR, Ferrario CM and Novick AC: Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol. 151:208–213. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Chatterjee PK, Weerackody RP, Mistry SK, Hawksworth GM and McLay JS: Selective antagonism of the AT1 receptor inhibits angiotensin II stimulated DNA and protein synthesis in primary cultures of human proximal tubular cells. Kidney Int. 52:699–705. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Z, Kelly DJ, Cox A, Casley D, Forbes JM, Martinello P, Dean R, Gilbert RE and Cooper ME: Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 58:2437–2351. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Dolley-Hitze T, Jouan F, Martin B, Mottier S, Edeline J, Moranne O, Le Pogamp P, Belaud-Rotureau MA, Patard JJ, Rioux-Leclercq N and Vigneau C: Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer. 103:1698–1705. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gonzalez-Villalobos RA, Shen XZ, Bernstein EA, Janjulia T, Taylor B, Giani JF, Blackwell WL, Shah KH, Shi PD, Fuchs S and Bernstein KE: Rediscovering ACE: Novel insights into the many roles of the angiotensin-converting enzyme. J Mol Med (Berl). 91:1143–1154. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, Jennette JC, O'Brien DA and Smithies O: Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature. 375:146–148. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Lin C, Datta V, Okwan-Duodu D, Chen X, Fuchs S, Alsabeh R, Billet S, Bernstein KE and Shen XZ: Angiotensin-converting enzyme is required for normal myelopoiesis. FASEB J. 25:1145–1155. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chappell MC: Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1–7)-MAS receptor axis: More than regulation of blood pressure? Hypertension. 50:596–599. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Takada Y, Hiwada K, Yokoyama M, Ochi K, Takeuchi M and Kokubu T: Angiotensin converting enzyme. A possible histologic indicator for human renal cell carcinoma. Cancer. 56:130–133. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Larrinaga G, Pérez I, Sanz B, Blanco L, López JI, Cándenas ML, Pinto FM, Gil J, Irazusta J and Varona A: Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul Pept. 165:218–223. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Usmani BA, Janeczko M, Shen R, Mazumdar M, Papandreou CN and Nanus DM: Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer. Br J Cancer. 82:550–552. 2000.PubMed/NCBI | |
|
de Martino M, Klatte T, Schatzl G, Waldert M, Remzi M, Haitel A, Kramer G and Marberger M: Insertion/deletion polymorphism of angiotensin I-converting enzyme gene is linked with chromophobe renal cell carcinoma. Urology. 77:1005.e9–1005.e13. 2011. View Article : Google Scholar | |
|
van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A and Stricker BH: Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism and cancer: The Rotterdam Study. Cancer. 112:748–757. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Deckers IA, van den Brandt PA, van Engeland M, van Schooten FJ, Godschalk RW, Keszei AP and Schouten LJ: Polymorphisms in genes of the renin-angiotensin-aldosterone system and renal cell cancer risk: Interplay with hypertension and intakes of sodium, potassium and fluid. Int J Cancer. 136:1104–1116. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Andreotti G, Boffetta P, Rosenberg PS, Berndt SI, Karami S, Menashe I, Yeager M, Chanock SJ, Zaridze D, Matteev V, et al: Variants in blood pressure genes and the risk of renal cell carcinoma. Carcinogenesis. 31:614–620. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kohara K, Brosnihan KB and Ferrario CM: Angiotensin(1–7) in the spontaneously hypertensive rat. Peptides. 14:883–891. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu T, Miller AG, Deliyanti D, Berka DR, Agrotis A, Campbell DJ and Wilkinson-Berka JL: Prorenin stimulates a pro-angiogenic and pro-inflammatory response in retinal endothelial cells and an M1 phenotype in retinal microglia. Clin Exp Pharmacol Physiol. 42:537–548. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shibayama Y, Fujimori T, Nguyen G, Hirose T, Totsune K, Ichihara A, Kitada K, Nakano D, Kobori H, Kohno M, et al: (Pro)renin receptor is crucial for Wnt/β-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Sci Rep. 5:88542015. View Article : Google Scholar : PubMed/NCBI | |
|
Trask AJ and Ferrario CM: Angiotensin-(1–7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev. 25:162–174. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yacoub R and Campbell KN: Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis. 8:29–40. 2015.PubMed/NCBI | |
|
Montana V and Sontheimer H: Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci. 31:4858–4867. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Williams RN, Parsons SL, Morris TM, Rowlands BJ and Watson SA: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 31:1042–1050. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
de Groot-Besseling RR, Ruers TJ, van Kraats AA, Poelen GJ, Ruiter DJ, de Waal RM and Westphal JR: Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. Int J Cancer. 112:329–334. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
McMurray J and Chopra M: Influence of ACE inhibitors on free radicals and reperfusion injury: Pharmacological curiosity or therapeutic hope? Br J Clin Pharmacol. 31:373–379. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng S, Yang Y, Song R, Yang X, Liu H, Ma Q, Yang L, Meng R, Tao T, Wang S and He J: Ang-(1–7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway. Biochem Biophys Res Commun. 460:333–340. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, Mezzano S, Egido J, Schultheiss HP, Ruiz-Ortega M and Walther T: Angiotensin-(1–7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS One. 4:e54062009. View Article : Google Scholar : PubMed/NCBI | |
|
Ni L, Feng Y, Wan H, Ma Q, Fan L, Qian Y, Li Q, Xiang Y and Gao B: Angiotensin-(1–7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol Rep. 27:783–790. 2012.PubMed/NCBI | |
|
Soto-Pantoja DR, Menon J, Gallagher PE and Tallant EA: Angiotensin-(1–7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther. 8:1676–1683. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Gallagher PE and Tallant EA: Inhibition of human lung cancer cell growth by angiotensin-(1–7). Carcinogenesis. 25:2045–2052. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Mukai H, Fitzgibbon WR, Bozeman G, Margolius HS and Ploth DW: Bradykinin B2 receptor antagonist increases chloride and water absorption in rat medullary collecting duct. Am J Physiol. 271:R352–R360. 1996.PubMed/NCBI | |
|
Bagaté K, Grima M, Imbs JL, Jong WD, Helwig JJ and Barthelmebs M: Signal transduction pathways involved in kinin B(2) receptor-mediated vasodilation in the rat isolated perfused kidney. Br J Pharmacol. 132:1735–1742. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
El-Dahr SS, Dipp S and Baricos WH: Bradykinin stimulates the ERK->Elk-1->Fos/AP-1 pathway in mesangial cells. Am J Physiol. 275:F343–F352. 1998.PubMed/NCBI | |
|
Moodley R, Snyman C, Odhav B and Bhoola KD: Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells. Biol Chem. 386:375–382. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kramarenko II, Morinelli TA, Bunni MA, Raymond JR Sr and Garnovskaya MN: The bradykinin B(2) receptor induces multiple cellular responses leading to the proliferation of human renal carcinoma cell lines. Cancer Manag Res. 4:195–205. 2012.PubMed/NCBI | |
|
Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL and Robertson JW: Do inhibitors of angiotensin-I-converting enzyme protect agains risk of cancer? Lancet. 352:179–184. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Yoon C, Yang HS, Jeon I, Chang Y and Park SM: Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: A meta-analysis of observational studies. CMAJ. 183:E1073–E1084. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fryzek JP, Poulsen AH, Johnsen SP, McLaughlin JK, Sørensen HT and Friis S: A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer. 92:1302–1306. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chin HJ, Oh SW, Goo HS, Oh J, Noh JW, Cho JT, Na KY, Kim S and Chae DW: Members of The PREMIER Group: Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis. J Korean Med Sci. 26:59–66. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wysocki PJ, Kwiatkowska EP, Kazimierczak U, Suchorska W, Kowalczyk DW and Mackiewicz A: Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin Cancer Res. 12:4095–4102. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK and Jonsson JR: Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer. 77:880–883. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Araujo WF, Naves MA, Ravanini JN, Schor N and Teixeira VP: Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice. Urol Oncol. 33:389.e1–e7. 2015. View Article : Google Scholar | |
|
McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R and Choueiri TK: Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 21:2471–2479. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tatokoro M, Fujii Y, Kawakami S, Saito K, Koga F, Matsuoka Y, Iimura Y, Masuda H and Kihara K: Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci. 102:137–143. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Miyajima A, Yazawa S, Kosaka T, Tanaka N, Shirotake S, Mizuno R, Kikuchi E and Oya M: Prognostic impact of renin-angiotensin system blockade on renal cell carcinoma after surgery. Ann Surg Oncol. 22:3751–3759. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H and Carducci MA: Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur J Cancer. 47:1955–1961. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Izzedine H, Derosa L, Le Teuff G, Albiges L and Escudier B: Hypertension and angiotensin system inhibitors: Impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol. 26:1128–1133. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD and Williams JS: Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 121:311–319. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sorich MJ, Kichenadasse G, Rowland A, Woodman RJ and Mangoni AA: Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials. Int J Cancer. 138:2293–2299. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Penttila P, Rautiola J, Poussa T, Peltola K and Bono P: Angiotensin inhibitors as treatment of Sunitinib/Pazopanib-induced hypertension in metastatic renal cell carcinoma. Clin Genitourin Cancer. 15:384–390.e3. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Huillard O, Xylinas E, Peyromaure M, Alexandre J and Goldwasser F: Angiotensin system inhibitors in renal cell carcinoma-letter. Clin Cancer Res. 22:5242016. View Article : Google Scholar : PubMed/NCBI | |
|
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al: Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 42:1206–1252. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS and Motzer RJ: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 103:763–773. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA and Humphreys BD: Supression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension. 56:1131–1136. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta R and Maitland ML: Sunitinib, hypertension, and heart failure: A model for kinase inhibitor-mediated cardiotoxicity. Curr Hypertens Rep. 13:430–435. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH and van den Meiracker AH: Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 56:675–681. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR and O'Dwyer PJ: Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol. 24:1363–1369. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ and Wedge SR: Inhibition of vascular endothelial growth factor-a signaling induces hypertension: Examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res. 14:3124–3131. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Siddiqui AJ, Mansson-Broberg A, Gustafsson T, Grinnemo KH, Dellgren G, Hao X, Fischer H and Sylvén C: Antagonism of the renin-angiotensin system can counteracts cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in normal heart. Am J Hyprtens. 18:1347–1352. 2005. View Article : Google Scholar | |
|
Agabiti-Rosei E: Structural and functional changes of the microcirculation in hypertension: Influence of pharmacological therapy. Drugs. 63:19–29. 2003.(In French). View Article : Google Scholar : PubMed/NCBI | |
|
Szmit S, Langiewicz P, Zlnierek J, Nurzyński P, Zaborowska M, Filipiak KJ, Opolski G and Szczylik C: Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res. 35:18–25. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu X, Stergiopoulos K and Wu S: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta Oncol. 48:9–17. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Nagasawa T, Khan Hye MA and Imig JD: Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clin Exp Pharmacol Physiol. 39:454–461. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH, Baelde HJ, Danser AH and van den Meiracker AH: Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: Preclinical study. Hypertension. 64:1282–1289. 2014. View Article : Google Scholar : PubMed/NCBI |
